EMPOWERING DENDRITIC CELLS
Amphera B.V., a late clinical stage biotechnology company, develops MesoPher cell therapy for the treatment of cancer. Our lead indications are mesothelioma and pancreatic cancer.
MesoPher is comprised of autologous dendritic cells loaded with our proprietary allogeneic tumour cell lysate PheraLys. PheraLys is a well-characterised, innovative source of a broad-spectrum of Tumour Associated Antigens. Several clinical studies with our lead product candidate MesoPher are ongoing.
- Results REACTIVE-2 clinical trial in metastatic pancreatic cancer published in Nature Communications
- MesoPher cell therapy increases 2-year RFS rate in resected pancreatic cancer by 50%; publication of phase II results in Journal of Clinical Oncology and Orphan Designation granted by FDA & EMA
- Positive results of phase II trial with MesoPher cell therapy in resected pancreatic cancer published in the Journal of Clinical Oncology
MEET US AT
BIO-Europe Spring
23–25 March 2026
Lisbon, Portugal